Horizon, Roche top list for pharma reputation among rare disease patient groups, survey finds

As rare dis­ease drug re­search in­creas­es among large phar­ma com­pa­nies, so do their rep­u­ta­tions with rare dis­ease pa­tient groups. The lat­est sur­vey in Pa­tientView’s an­nu­al re­search found that 57% of pa­tient ad­vo­cates say the phar­ma in­dus­try’s rep­u­ta­tion is “good” or “ex­cel­lent.” That’s up from 33% five years ago.

Hori­zon, Roche and Take­da lead the in­di­vid­ual com­pa­nies’ rep­u­ta­tion list among pa­tient groups who are fa­mil­iar with those phar­mas. When asked specif­i­cal­ly about 15 of the largest glob­al phar­mas, pa­tient groups named Roche, Take­da and Pfiz­er in the top three spots. Among the phar­ma com­pa­nies that made the most progress with rare dis­ease pa­tients this year were UCB (up 5% year over year) and both As­traZeneca and Oc­taphar­ma (up 4%).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.